Clinical Trials

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma


Study ID
Amgen INTREPID - 20160104

NCT Number
NCT02939183 (Click on the NCT number for more information about the trial)

Research Study Number
2019-0167

Principle Investigator
Dr. David Siegel

Phase
I

Sponsor
Amgen/Onyx


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now